Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-26
2010-12-21
Eyler, Yvonne L (Department: 1619)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000, C514S416000, C514S023000, C514S159000, C514S171000, C514S570000, C514S254090
Reexamination Certificate
active
07855223
ABSTRACT:
The present invention is directed to a method for treating inflammatory arthritis in a mammal. The method typically comprises administering to an animal a therapeutically effective amount of at least one compound selected from indigo, isoindigo, indirubin or derivatives thereof, such as NATURA-α or NATURA. The present invention is further directed to pharmaceutical compositions that include a therapeutically effective amount of at least one compound of the invention, an anti-inflammatory arthritis agent and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 3995030 (1976-11-01), Malachowski
patent: 4113881 (1978-09-01), Diehl
patent: 4118484 (1978-10-01), Wechter et al.
patent: 4172889 (1979-10-01), Wechter et al.
patent: 4176179 (1979-11-01), Gainer
patent: 4322405 (1982-03-01), Schulthess et al.
patent: 4375468 (1983-03-01), Dunn
patent: 4468398 (1984-08-01), Johnson et al.
patent: 4500533 (1985-02-01), Matsumoto
patent: 4525345 (1985-06-01), Dunn et al.
patent: 4533551 (1985-08-01), Martel
patent: 4732752 (1988-03-01), Stephan
patent: 4968510 (1990-11-01), Jensen
patent: 5026538 (1991-06-01), Lieberman et al.
patent: 5061475 (1991-10-01), Lieberman et al.
patent: 5061724 (1991-10-01), Gertner
patent: 5098899 (1992-03-01), Gilbert et al.
patent: 5149688 (1992-09-01), Ando et al.
patent: 5342615 (1994-08-01), Nakai et al.
patent: 5389617 (1995-02-01), Drell
patent: 5399347 (1995-03-01), Trentham et al.
patent: 5511563 (1996-04-01), Diamond
patent: 5567409 (1996-10-01), Aizawa et al.
patent: 5696092 (1997-12-01), Pattierno et al.
patent: 5720955 (1998-02-01), Weiner et al.
patent: 5770357 (1998-06-01), Douvas et al.
patent: 5782792 (1998-07-01), Jones et al.
patent: 5783188 (1998-07-01), Weiner et al.
patent: 5843445 (1998-12-01), Weiner et al.
patent: 5843919 (1998-12-01), Burger
patent: 5849323 (1998-12-01), Braswell et al.
patent: 5849336 (1998-12-01), Aoyagi et al.
patent: 5856446 (1999-01-01), Weiner et al.
patent: 5905083 (1999-05-01), Cincotta et al.
patent: 5952367 (1999-09-01), Pak
patent: 6033672 (2000-03-01), Douvas et al.
patent: 6040306 (2000-03-01), Batts et al.
patent: 6083906 (2000-07-01), Troutt
patent: 6087382 (2000-07-01), Bonner, Jr. et al.
patent: 6197776 (2001-03-01), Bonner, Jr. et al.
patent: 6204242 (2001-03-01), Bae et al.
patent: 6346519 (2002-02-01), Petrus
patent: 6353024 (2002-03-01), Grouhel et al.
patent: 6369082 (2002-04-01), Lacombe et al.
patent: 6372794 (2002-04-01), Nimni
patent: 6465473 (2002-10-01), Bonner, Jr. et al.
patent: 6566341 (2003-05-01), Wang et al.
patent: 6610728 (2003-08-01), Macias
patent: 6613800 (2003-09-01), Smith
patent: 6656925 (2003-12-01), Petrus
patent: 6933315 (2005-08-01), Wang et al.
patent: 7098184 (2006-08-01), Godfrey et al.
patent: 2002/0132792 (2002-09-01), Prien et al.
patent: 2005/0090426 (2005-04-01), Blumberg
patent: 2005/0154046 (2005-07-01), Wang et al.
patent: 2005/0197381 (2005-09-01), Wang et al.
patent: 100 53 474 (2002-05-01), None
patent: 0 987 027 (2000-03-01), None
patent: 61007254 (1986-01-01), None
patent: WO 99/62503 (1999-12-01), None
patent: WO 00/61124 (2000-10-01), None
patent: WO 00/61555 (2000-10-01), None
patent: WO/02/074742 (2002-09-01), None
patent: WO/02/092079 (2002-11-01), None
patent: WO/02/100401 (2002-12-01), None
patent: WO/03/051900 (2003-06-01), None
Nonomura et al. Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21cip1 gene into the joints, International Immunology, Jun. 2001, vol. 13, No. 6 pp. 723-731.
Barnes et al. Nuclear Factor kB—A Pivotal Transcription Factor in Chronic INflammatory Diseases, New England Journal of Medicine, Apr. 10, 1997, vol. 335, No. 15 pp. 1066-1071.
Tu Caixia et al., A Study on the Pharmacoogical Activities of Four Kinds of Di-Indole Compounds and Exploration of its Clinical Significance, Zhonghua Pifuke Zazhi, 1991, vol. 24, No. 4, pp. 245-247, 287 see reference and translation.
Watanabe, T. et al., “Artherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis”,Int J Cardiol, 66 Suppl 1:S45-53; discussion S55 (1998).
Weinberg, J. et al., “Biologic Therapy for Psoriasis—The First Wave: Infliximab, Etanercept, Efalizumab, and Alefacept”,J. Drugs Dermatol, 3:303-310 (2002).
Weisman, M. H., “What are the risks of biologic therapy in rheumatoid arthritis? An update on safety”,J. Rheumatol Suppl., 65:33-38 (2002).
Whalen, J. D. et al., “Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws”,J Immunol, 162:3625-3632 (1999).
Wicki, A. et al., “The Rho/Rho-kinase and the phosphatidylinositol 3-kinase pathways are essential for spontaneous locomotion of Walker 256 carcinosarcoma cells,”Int J Cancer, vol. 91, No. 6, pp. 763-771 (2001).
Williams, J. D. and Griffiths, C. E., “Cytokine blocking agents in dermatology”,Clin Exp Dermatol, 27:585-590 (2002).
Written Opinion of the International Search Authority for PCT/US05/00169 dated Jul. 19, 2005.
Wu-Wong, J. R., et al., “Identification and characterization of A-105972, an antineoplastic agent,”Cancer Res, vol. 61, No. 4, pp. 1486-1492 (2001).
Yamaura, T., et al., “Model for mediastinal lymph node metastasis produced by orthotopic intrapulmonary implantation of lung cancer cells in mice,”Hum Cell, vol. 12, No. 4, pp. 197-204 (1999).
Yoon, J. W. et al., Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells,Autoimmunity, 27:109-122 (1998).
Yoza, B. K. et al., “Protein-tyrosine kinase activation is required for lipopolysaccharide inducution of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation”,J Biol Chem, 271:18306-18309 (1996).
Zhang, H. et al., “Advances in Experimental Studies on Treatment of Psoriasis by Traditional Chinese Medicine”,J Tradit Chin Med, 22(1):61-66 (Mar. 2002) (Abstract only).
European Search Report for European Application No. 02805123 dated Nov. 16, 2007.
Wahl et al., “Syntheses dans le groupe des indigoides (II). Nouvelles syntheses de l'ecarlate thioindigo et de l'indirubine Asyntheses in the indigoid group. II. New syntheses of scarlot thioindigo andindirubinU”,Bulletin De La Societe Chimique De France, Memoires, Masson, Paris, France, (1914) pp. 336-342—English Translation of p. 339, paragraph 4.
Wahl et al., “Chimie Organique.—un nouvel isomere de l'indigo”,Comptes Rendus Hebdomadaires Des Seances De L'Academie Des Sciences, Gauthier-Villars, Paris, France, vol. 148, (1909) pp. 714-720—English Translation of p. 718, paragraph 1.
Stolle et al., “N-Substituted oxindoles and isatins”,Journal Fuer Praktische Chemie(Leipzig), vol. 128, pp. 1-43—English Translation of p. 34, Example 2.
International Search Report for PCT/US2002/039866 dated Mar. 19, 2003.
International Preliminary Examination Report for PCT/US2002/039866 dated May 13, 2004.
U.S. Appl. No. 60/407,267 entitled “Derivative of Isoindigo, Indigo and Indirubin for the Treatment of Cancer” filed Sep. 3, 2002.
Stolle et al., “N-Substituted oxindoles and isatins”,Journal Fuer Praktische Chemie(Leipzig), vol. 128, pp. 1-43—English Translation of p. 34, Example 2 (1930).
Isatis tinctoria, Alternative Medicine Review, 7(6):523-524 (2002).
Drug Facts and Comparisons, Wolters Kluwer Co., pp. 1210-1213 (1994).
European Office Action for European Application No. 05704992.6 dated Mar. 4, 2009 (5 sheets).
Alessi, D. R., et al., “PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo,”J Biol Chem, vol. 270, No. 46, pp. 27489-27494 (1995).
Andreakos, E.T. et al., “Cytokines and anti-cytokine biologicals in autoimmunit
Chen Ruihuan
Liu Xiao Mei
Mencher Simon K.
Tsao Allen
Wang Longgui
Eyler Yvonne L
Fennemore Craig P.C.
Jagoe Donna
Natrogen Therapeutics International, Inc.
LandOfFree
Method of treating inflammatory arthritis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating inflammatory arthritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating inflammatory arthritis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237266